Every 424B that Amylyx Pharmaceuticals (AMLX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AMLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMLX filings page.
Amylyx Pharmaceuticals, Inc. (AMLX) is conducting a primary offering of 14,090,000 shares of common stock at a public offering price of $35.50 per share under its Form S-3 shelf registration. Underwriters have a 30-day option to purchase up to 2,113,500 additional shares at the public offering price less underwriting discounts and commissions.
Gross proceeds are expected to be $500.2 million (or $575.2 million if the option is exercised in full), with net proceeds to Amylyx of approximately $471.7 million (or $542.5 million with full option exercise) after underwriting discounts, commissions and estimated expenses. As of June 30, 2026, 111,368,283 shares of common stock were outstanding.
Amylyx plans to use the net proceeds, together with existing cash, cash equivalents and marketable securities, to fund the potential U.S. commercial launch of its lead investigational drug avexitide for post-bariatric hypoglycemia if approved, including securing commercial manufacturing capacity, and for research and development, working capital and other general corporate purposes. The company disclosed that the offering will cause immediate dilution of $29.83 per share to new investors based on the offering price.
Amylyx Pharmaceuticals, Inc. (AMLX) is conducting a primary offering of up to $350,000,000 of its common stock under an effective shelf registration. The shares trade on Nasdaq Global Select Market under the symbol AMLX, with a closing price of $35.11 on August 18, 2026.
Amylyx is a pre-commercial pharmaceutical company focused on endocrine and neurodegenerative diseases. Its lead asset, avexitide, a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism, has U.S. FDA Breakthrough Therapy, Rare Pediatric Disease and Orphan Drug Designations. The Phase 3 LUCIDITY trial in PBH met its FDA-agreed primary endpoint, showing a 55% reduction in Level 2 and 3 hypoglycemic events versus placebo (p=0.000003), with a generally favorable safety profile.
The company plans to submit a New Drug Application for avexitide by the end of 2026 and is arranging commercial supply through contract manufacturers. Other programs include AMX0035 in Wolfram syndrome, AMX0114 in ALS, and long-acting GLP-1 antagonist AMX0318. Net proceeds will be used with existing cash to fund a potential U.S. avexitide launch, expand manufacturing capacity, and support R&D, working capital and general corporate purposes, while existing shareholders will experience dilution from this equity issuance.